These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27685167)

  • 1. Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma.
    Babiker HM; Riaz IB; Shah SR; Von Hoff DD; Borad MJ
    Anticancer Drugs; 2017 Feb; 28(2):127-132. PubMed ID: 27685167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia: Friend or Foe for drug delivery in Pancreatic Cancer.
    Shah VM; Sheppard BC; Sears RC; Alani AW
    Cancer Lett; 2020 Nov; 492():63-70. PubMed ID: 32822815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
    Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
    Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent activation of pancreatic stellate cells creates a microenvironment favorable for the malignant behavior of pancreatic ductal adenocarcinoma.
    Tang D; Wang D; Yuan Z; Xue X; Zhang Y; An Y; Chen J; Tu M; Lu Z; Wei J; Jiang K; Miao Y
    Int J Cancer; 2013 Mar; 132(5):993-1003. PubMed ID: 22777597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.
    Bobrov E; Skobeleva N; Restifo D; Beglyarova N; Cai KQ; Handorf E; Campbell K; Proia DA; Khazak V; Golemis EA; Astsaturov I
    Oncotarget; 2017 Jan; 8(3):4399-4409. PubMed ID: 27779106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic ascorbate induces transient hypoxia sensitizing pancreatic ductal adenocarcinoma to a hypoxia activated prodrug.
    Kishimoto S; Crooks DR; Yasunori O; Kota Y; Yamamoto K; Linehan WM; Levine M; Krishna MC; Brender JR
    Free Radic Biol Med; 2024 Sep; 222():579-587. PubMed ID: 38992394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pancreas cancer microenvironment.
    Feig C; Gopinathan A; Neesse A; Chan DS; Cook N; Tuveson DA
    Clin Cancer Res; 2012 Aug; 18(16):4266-76. PubMed ID: 22896693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophages and pancreatic ductal adenocarcinoma.
    Habtezion A; Edderkaoui M; Pandol SJ
    Cancer Lett; 2016 Oct; 381(1):211-6. PubMed ID: 26708507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microenvironmental factors and extracellular matrix degradation in pancreatic cancer.
    Binker MG; Binker-Cosen MJ; Binker-Cosen AA; Cosen-Binker LI
    JOP; 2014 Jul; 15(4):280-5. PubMed ID: 25076320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate Radiotherapy.
    Kishimoto S; Brender JR; Chandramouli GVR; Saida Y; Yamamoto K; Mitchell JB; Krishna MC
    Antioxid Redox Signal; 2021 Oct; 35(11):904-915. PubMed ID: 32787454
    [No Abstract]   [Full Text] [Related]  

  • 11. Increased fibrosis and impaired intratumoral accumulation of macromolecules in a murine model of pancreatic cancer co-administered with FGF-2.
    Sakai S; Iwata C; Tanaka HY; Cabral H; Morishita Y; Miyazono K; Kano MR
    J Control Release; 2016 May; 230():109-15. PubMed ID: 27080571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of hypoxia in pancreatic cancer: a potential therapeutic target?
    Erkan M; Kurtoglu M; Kleeff J
    Expert Rev Gastroenterol Hepatol; 2016; 10(3):301-16. PubMed ID: 26560854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory cytokines in human pancreatic cancer.
    Roshani R; McCarthy F; Hagemann T
    Cancer Lett; 2014 Apr; 345(2):157-63. PubMed ID: 23879960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer.
    Baker AF; Koh MY; Williams RR; James B; Wang H; Tate WR; Gallegos A; Von Hoff DD; Han H; Powis G
    Pancreas; 2008 Mar; 36(2):178-86. PubMed ID: 18376310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Survival Pathways MAPK and NF-kB Triggers Apoptosis in Pancreatic Ductal Adenocarcinoma Cells via Suppression of Autophagy.
    Papademetrio DL; Lompardía SL; Simunovich T; Costantino S; Mihalez CY; Cavaliere V; Álvarez É
    Target Oncol; 2016 Apr; 11(2):183-95. PubMed ID: 26373299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix control of pancreatic cancer: New insights into fibronectin signaling.
    Topalovski M; Brekken RA
    Cancer Lett; 2016 Oct; 381(1):252-8. PubMed ID: 26742464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel drug targets based on association between inflammation and pancreatic ductal adenocarcinoma.
    Saif MW
    JOP; 2010 Jul; 11(4):403-4; author reply 411. PubMed ID: 20601821
    [No Abstract]   [Full Text] [Related]  

  • 18. A newly developed anti-Mucin 13 monoclonal antibody targets pancreatic ductal adenocarcinoma cells.
    Nishii Y; Yamaguchi M; Kimura Y; Hasegawa T; Aburatani H; Uchida H; Hirata K; Sakuma Y
    Int J Oncol; 2015 Apr; 46(4):1781-7. PubMed ID: 25672256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retinoic acid inhibits pancreatic cancer cell migration and EMT through the downregulation of IL-6 in cancer associated fibroblast cells.
    Guan J; Zhang H; Wen Z; Gu Y; Cheng Y; Sun Y; Zhang T; Jia C; Lu Z; Chen J
    Cancer Lett; 2014 Apr; 345(1):132-9. PubMed ID: 24334138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma.
    Byrne JD; Jajja MR; Schorzman AN; Keeler AW; Luft JC; Zamboni WC; DeSimone JM; Yeh JJ
    Proc Natl Acad Sci U S A; 2016 Feb; 113(8):2200-5. PubMed ID: 26858448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.